Enzymotec

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Enzymotec sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials none currently recruiting 2 completed upper quartile by trial count

Enzymotec: 3 sponsored US clinical trials, none currently recruiting.

Enzymotec sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. The most-studied condition in this pipeline is Autistic Disorder, with 1 trials.

Upper-quartile sponsor footprint

Enzymotec sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

3 total, page 1 of 1

COMPLETED NA

Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT02257216
TERMINATED NA

Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment

NCT02211560
COMPLETED NA

An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)

NCT02222285

Therapeutic Areas

Autistic Disorder 1

How the Enzymotec archive is shaped

3 indexed studies, none listed as recruiting (0% open); 2 completed (67%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Autistic Disorder (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Enzymotec: archived-pipeline peers nationwide

Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Enzymotec sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Enzymotec10xBio22nd Century GroupAA SecordAAADRS Clinical Research Center23andMe3-C Institute for Social Development3 Waves Wellness3EO Health
Enzymotec sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Enzymotec sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Enzymotec page

3 registered trials is a research-attention snapshot, not an endorsement of Enzymotec or any single study.

  • None of Enzymotec's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Autistic Disorder is the condition Enzymotec studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Autistic Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Enzymotec pipeline card: 3 registered trials from official public datasets.Report a data error.